According to Zen Score, the 3 best biotechnology stocks to buy right now are:
1. Corcept Therapeutics (NASDAQ:CORT)
Corcept Therapeutics (NASDAQ:CORT) is the top biotech stock with a Zen Score of 67, which is 45 points higher than the biotech industry average of 22. It passed 22 out of 33 due diligence checks and has strong fundamentals. Corcept Therapeutics has seen its stock return 14.42% over the past year, overperforming other biotech stocks by 35 percentage points.
Corcept Therapeutics has an average 1 year
price target of $40.67, an upside of 47.72% from Corcept Therapeutics's current stock price of $27.53.
Corcept Therapeutics stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Corcept Therapeutics, 66.67% have issued a Strong Buy rating, 33.33% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
2. Incyte (NASDAQ:INCY)
Incyte (NASDAQ:INCY) is the second best biotech stock with a Zen Score of 64, which is 42 points higher than the biotech industry average of 22. It passed 20 out of 33 due diligence checks and has strong fundamentals. Incyte has seen its stock lose -12.99% over the past year, overperforming other biotech stocks by 7 percentage points.
Incyte has an average 1 year
price target of $74.92, an upside of 30.07% from Incyte's current stock price of $57.60.
Incyte stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Incyte, 30.77% have issued a Strong Buy rating, 23.08% have issued a Buy, 46.15% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
3. Harmony Biosciences Holdings (NASDAQ:HRMY)
Harmony Biosciences Holdings (NASDAQ:HRMY) is the third best biotech stock with a Zen Score of 62, which is 40 points higher than the biotech industry average of 22. It passed 21 out of 33 due diligence checks and has strong fundamentals. Harmony Biosciences Holdings has seen its stock lose -17.3% over the past year, overperforming other biotech stocks by 3 percentage points.
Harmony Biosciences Holdings has an average 1 year
price target of $39.80, an upside of 31.7% from Harmony Biosciences Holdings's current stock price of $30.22.
Harmony Biosciences Holdings stock has a consensus Hold recommendation according to Wall Street analysts. Of the 5 analysts covering Harmony Biosciences Holdings, 40% have issued a Strong Buy rating, 20% have issued a Buy, 0% have issued a hold, while 20% have issued a Sell rating, and 20% have issued a Strong Sell.